These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 31142371)

  • 21. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
    Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
    J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo.
    Huang HL; Lee HY; Tsai AC; Peng CY; Lai MJ; Wang JC; Pan SL; Teng CM; Liou JP
    PLoS One; 2012; 7(8):e43645. PubMed ID: 22928010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.
    Walters DM; Lindberg JM; Adair SJ; Newhook TE; Cowan CR; Stokes JB; Borgman CA; Stelow EB; Lowrey BT; Chopivsky ME; Gilmer TM; Parsons JT; Bauer TW
    Neoplasia; 2013 Feb; 15(2):143-55. PubMed ID: 23441129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells.
    Zhou S; Xia H; Xu H; Tang Q; Nie Y; Gong QY; Bi F
    J Exp Clin Cancer Res; 2018 Sep; 37(1):218. PubMed ID: 30185207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
    Yuan X; Tang Z; Du R; Yao Z; Cheung SH; Zhang X; Wei J; Zhao Y; Du Y; Liu Y; Hu X; Gong W; Liu Y; Gao Y; Huang Z; Cao Z; Wei M; Zhou C; Wang L; Rosen N; Smith PD; Luo L
    Mol Oncol; 2020 Aug; 14(8):1833-1849. PubMed ID: 32336014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target.
    Du X; He K; Huang Y; Xu Z; Kong M; Zhang J; Cao J; Teng L
    Int J Oncol; 2020 Mar; 56(3):761-771. PubMed ID: 32124956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models.
    Sakamoto T; Ozaki K; Fujio K; Kajikawa SH; Uesato S; Watanabe K; Tanimura S; Koji T; Kohno M
    Biochem Biophys Res Commun; 2013 Apr; 433(4):456-62. PubMed ID: 23501104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells.
    Qin Y; Zhao X; Fang Y
    Int J Gynecol Cancer; 2014 Oct; 24(8):1373-80. PubMed ID: 25188886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
    Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
    Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
    Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
    Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
    Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
    Junttila MR; Devasthali V; Cheng JH; Castillo J; Metcalfe C; Clermont AC; Otter DD; Chan E; Bou-Reslan H; Cao T; Forrest W; Nannini MA; French D; Carano R; Merchant M; Hoeflich KP; Singh M
    Mol Cancer Ther; 2015 Jan; 14(1):40-7. PubMed ID: 25376606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.
    Cavalloni G; Peraldo-Neia C; Varamo C; Chiorino G; Sassi F; Aglietta M; Leone F
    Oncotarget; 2016 Aug; 7(32):52354-52363. PubMed ID: 27429047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pharmacogenomic analysis using L1000CDS
    Choi EA; Choi YS; Lee EJ; Singh SR; Kim SC; Chang S
    Cancer Lett; 2019 Nov; 465():82-93. PubMed ID: 31404615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway.
    Yang L; Lin S; Kang Y; Xiang Y; Xu L; Li J; Dai X; Liang G; Huang X; Zhao C
    J Exp Clin Cancer Res; 2019 Jan; 38(1):31. PubMed ID: 30674340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
    Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
    Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
    Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
    J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.
    Brauswetter D; Gurbi B; Varga A; Várkondi E; Schwab R; Bánhegyi G; Fábián O; Kéri G; Vályi-Nagy I; Peták I
    PLoS One; 2017; 12(9):e0185687. PubMed ID: 28957417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.